<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns:ifp="http://www.ifactory.com/press" xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9">
  <ifp:contentType>ARTICLE</ifp:contentType>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/12/4/article-p449.xml</sm:loc>
    <ifp:title>The Changing Face of Community Practice: The New Normal</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/12/4/article-p451.xml</sm:loc>
    <ifp:title>Correspondence</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/12/4/article-p452.xml</sm:loc>
    <ifp:title>Correspondence</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/12/4/article-p455.xml</sm:loc>
    <ifp:title>Part 2: Abstracts from the NCCN 19th Annual Conference: Advancing the Standard of Cancer Care™</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/12/4/article-p465.xml</sm:loc>
    <ifp:title>Multiple Successful Desensitizations to Brentuximab Vedotin: A Case Report and Literature Review</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/12/4/article-p473.xml</sm:loc>
    <ifp:title>Soft Tissue Sarcoma, Version 2.2014</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/12/4/article-p488.xml</sm:loc>
    <ifp:title>Survivorship: Pain Version 1.2014</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/12/4/article-p502.xml</sm:loc>
    <ifp:title>Advances in Supportive Care for Multiple Myeloma</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/12/4/article-p513.xml</sm:loc>
    <ifp:title>Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/12/4/article-p527.xml</sm:loc>
    <ifp:title>Management of Patients With Cytogenetically Normal Acute Myeloid Leukemia Who Have Neither Favorable nor Unfavorable Markers</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/12/4/article-p542.xml</sm:loc>
    <ifp:title>Breast Cancer Version 3.2014</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/12/4/article-p591.xml</sm:loc>
    <ifp:title>Pertuzumab in the Treatment of HER2+ Breast Cancer</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/12/4/article-p599.xml</sm:loc>
    <ifp:title>Renaming Ductal Carcinoma in Situ: Would Removing “Carcinoma” Reduce Overtreatment?</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/12/4/article-pxxi.xml</sm:loc>
    <ifp:title>NCCN News</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/12/4/article-pxxxvi.xml</sm:loc>
    <ifp:title>Oncology Research Program</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
</urlset>
